6th September, 2025

ChameLogK: A Rapid, High-Throughput Assay to Assess Bioavailability of Beyond Rule of Five Compounds

ChameLogK is a cutting-edge method for measuring chameleonicity, a vital factor in assessing cell permeability propensity of small molecules, including ‘Beyond Rule-of-Five’ such as PROTACs, macrocycles and peptides. Chameleonicity is ability of molecules to conformationally adapt to their environment, driven by intramolecular hydrogen bonds; ChameLogK combines lipophilicity (BRlogD) and polarity (Δlog kw IAM) descriptors. Leveraging literature methods, o2h has developed a reliable, high-throughput platform to rapidly and inexpensively measure chameleonicity, accelerating optimization of Beyond Rule-ofFive therapeutic compounds

4th February, 2025

An array of Targeted Degradation approaches offered as a part of integrated drug discovery services

Explore how o2h Discovery applies a PROTAC-like approach to RNA-targeted drug discovery. Our expertise in small molecule design, assay development, and RIBOTACs enables the creation of novel RNA degraders for next-generation therapeutics.

3rd February, 2025

Integrated drug discovery services from o2h: Advancing therapeutic innovation through collaborative research

Our Integrated Drug Discovery approach combines biology, chemistry, and ADME capabilities to accelerate the design-make-test-analyze cycles across a broad range of therapeutic areas.

1st January, 2025

High-content analysis of DNA damage markers in multiplexed cell lines using the SemaCyte® microcarrier platform

High-content imaging (HCI) offers a considerable depth of analysis options when considering the requirements for developing a new cellular assay.